<DOC>
	<DOC>NCT01220518</DOC>
	<brief_summary>This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.</brief_summary>
	<brief_title>Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>diagnosed with active ankylosing spondylitis BASDAI score ≥ 4 and visual analogue scale(VAS) score of spinal pain ≥ 4 have total ankylosing of spine have allergies to infliximab serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>